Skip to main content

Articles

Conference Correspondent

Effects of Blisibimod on Renal and Inflammation Biomarkers and on Serum Immunoglobulin and Infection Risk in Patients with Lupus: Results from the PEARL-SC and Open-Label Extension Studies

Conference Correspondent

Safety and Efficacy of Epratuzumab in Patients with Lupus Confirmed in a Long-Term Open-Label Extension Study

Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea

Rosacea: The Patients Pay the Price

Conference Correspondent

Corticosteroid Use Reduced across 52 Weeks of Belimumab Therapy in Patients with Lupus: Combined Analyses from the BLISS Trials

Conference Correspondent

Belimumab Shows Clinical Response and Sustained Reductions in Circulating B Cells and in IgG Levels in Patients with Lupus

Conference Correspondent

Postmarketing Experience with Belimumab in Patients with Lupus in Clinical Practice Settings Confirms the Evidence from Clinical Trials

Conference Correspondent

High Levels of Interferon Type I in Plasma of Patients with Lupus Predict Future Renal Disease

Conference Correspondent

Biomarkers that Predict Development or Worsening of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

Conference Correspondent

Can MDHAQ/RAPID3 Be Used in Usual Care of Patients with Systemic Lupus Erythematosus?

Page 163 of 244
Results 1621 - 1630 of 2436